Business
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products,
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GL8WCCgrHOHP9r8Vdi7XpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) --","length":236,"tagName":"p"},{"type":"text","content":"ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update.","length":360,"tagName":"p"},{"type":"text","content":"Corporate Highlights from 1Q 2025 to date","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced FemBloc permanent birth control delivery system approval in Europe; FemBloc blended polymer component successfully completed an expedited G12 Special MDR Audit for Class III devices, and the Notified Body has recommended for CE mark approval pending the final stages of European Medical Agency (EMA) review","length":316,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced United Kingdom and Israeli regulatory approvals for FemaSeed and two diagnostic devices","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced partnership with CNY Fertility, a national conglomerate of eleven fertility centers, to offer FemaSeed","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced distribution partnerships for FemBloc in Spain","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced peer-reviewed publication of positive safety and efficacy results from FemBloc clinical trials","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Annou...